Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Global health price tag could be $371 billion a year by 2030, WHO says

Meeting life-saving global health targets by 2030 could require investments by donors and national governments of up to $58 per person per year, or $371 billion annually, the World Health Organization (WHO) said.

Read More »

Smartphone Controlled Vision is Coming

For the first time, EPGL reveals the “Omega” contact lens under development with InWith Corp. The patent pending “Omega” is designed to correct vision anytime by changing the curvature of the lenses on-demand, via smart phone or other mobile devices.

Read More »

Valeant Dumps Another Asset in Cash Deal

Valeant Pharmaceuticals is selling its Obagi Medical Products business to Haitong International Zhonghua Finance Acquisition Fund I for $190 million in cash.

Read More »

Safety Issues Force the FDA to Turn Down Amgen, UCB’s Osteoporosis Drug

The U.S. Food and Drug Administration rejected Amgen’s and UCB’s Biologics License Application for Evenity (romosozumab) for postmenopausal women with osteoporosis.

Read More »

Radius Health’s Longtime CEO Out, Former Novo Nordisk Exec Named New Leader

As Radius Health moves forward following the April 2017 approval of osteoporosis drug Tymlos, the company will do so with a new leader at the helm.

Read More »

CHMP Issues a Positive Opinion for Daiichi Sankyo’s Once-Daily Lixiana in Patients with Atrial Fibrillation Undergoing Cardioversion

Daiichi Sankyo Europe GmbH announced that the European Committee for Medicinal Products for Human Use (CHMP) recommended approval of a label update for the company’s oral, once-daily direct factor Xa-inhibitor Lixiana, to provide guidance on its use in patients undergoing transoesophageal echocardiography (TEE)-guided and delayed cardioversion (treatment to restore a normal heart rhythm).

Read More »

Same Condition, Different Costs: Should Patients Pay Different Amounts?

The National Pharmaceutical Council will host a webinar, “Same Condition, Different Costs: Should Patients Pay Different Amounts?” to discuss the practical realities of different cost-sharing models for prescription drugs.

Read More »

Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In Kyprolis Label

Amgen announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and a variation to the marketing application to the European Medicines Agency to include overall survival data from the Phase 3 head-to-head ENDEAVOR trial in the product information for Kyprolis (carfilzomib).

Read More »

Novartis stocks drug cabinet with “Big-3” arthritis blockbusters

Switzerland’s Novartis is stocking up cheaper versions of the world’s top-selling arthritis medicines, hoping a broad portfolio gives it an edge on rivals with narrower offerings.

Read More »

How AstraZeneca’s Silence Led to a $4 Billion Loss Overnight

As rumors swirled about whether or not AstraZeneca Chief Executive Officer Pascal Soriot was leaving for Israel-based Teva Pharmaceutical, investors expressed their concerns with a sell off that cost the British company $4 billion overnight.

Read More »

FDA Gives Nod to J&J’s Tremfya

FDA approved Janssen Biotech’s Tremfya (guselkumab) for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Read More »

Anthem files lawsuit against Insys Therapeutics

Health insurer Anthem Inc. filed a lawsuit against Insys Therapeutics Inc., alleging the drugmaker fraudulently obtained reimbursements for its opioid painkiller Subsys.

Read More »

How to Lead in a “Do More with Less” Environment

From the leaders of marketing teams to medical affairs, pharma executives are increasingly required to do more with less. While this is true across industries, the U.S. biopharma industry is faced with unique headwinds.

Read More »

FDA Advisory Committee Unanimously Recommends Approval of Mylan and Biocon’s Proposed Biosimilar Trastuzumab

Mylan N.V. and Biocon Ltd. announced that the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee recommended approval of the companies’ proposed biosimilar trastuzumab.

Read More »

Doctors, nurses among hundreds charged with defrauding U.S. health programs

More than 400 people – including doctors and nurses – have been charged with defrauding Medicare and other federal healthcare programs of $1.3 billion, with many accused of illegally distributing opioids and other narcotics, the Justice Department said.

Read More »

Five Key Digital Insights for Your Brand from Digital Pharma West

From the latest in VR to imaginative Social Engagement approaches, here are Ben Putman’s Top Five Digital Marketing takeaways for 2017.

Read More »

What Healthcare Marketers Can Learn from Netflix

A recent article in the New York Times, headlined Netflix Lets Viewers Pick the Plot, tells how the video streaming behemoth is creating content with an interactive twist.

Read More »

U.S. Senate Republicans unveil new healthcare bill amid deep divisions

Senate Republican leaders, aiming to salvage efforts backed by President Donald Trump to dismantle the Obamacare law, unveiled revised healthcare legislation that lets insurers sell bare-bones policies and retains key taxes on the wealthy.

Read More »

Stryker awarded $248.7 million in patent case against Zimmer

A U.S. judge increased the amount medical device maker Zimmer Biomet Holdings Inc. must pay Stryker Corp. for infringing patents on a surgical cleaning wand to $248.7 million following a ruling by the U.S. Supreme Court.

Read More »

Pfizer Announces FDA Accepts Supplemental New Drug Application for Xeljanz for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

Pfizer Inc. announced that the supplemental New Drug Application for Xeljanz (tofacitinib citrate), an investigational oral treatment for adult patients with moderately to severely active ulcerative colitis, has been accepted for filing by the U.S. Food and Drug Administration.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom